


In IgA nephropathy, sparsentan protects the glomerulus by simultaneously blocking ET-1 and Ang-II^{1,2}

Sparsentan is a novel, non-immunosuppressive, Dual Endothelin Angiotensin Receptor Antagonist (DEARA)^{2,3}



Sparsentan targets glomerular injury, reducing proteinuria and inflammation, and preserving kidney function^{2,4}

EFFECTS:

Anti-inflammatory⁵

Anti-proliferative^{6-8*}

Anti-fibrotic^{8,9*}

Anti-proteinuric¹⁰

*These effects are based on pre-clinical animal modeling data.

AT₁R, angiotensin II subtype 1 receptor; **DEARA**, Dual Endothelin Angiotensin Receptor Antagonist; **ET-1**, endothelin 1; **ET_AR**, endothelin type A receptor; **IgA**, immunoglobulin A.

1. Knoppova B et al. *J Clin Med*. 2021;10(19):4501; 2. Kohan DE et al. *Clin Sci*. 2024;138(11):645-662; 3. Trachtman H et al. *Expert Rev Clin Immunol*. 2024;20(6):571-576; 4. FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Traverse Therapeutics, Inc. 9/2024. 5. Cheung CK et al. Presented at: American Society of Nephrology, 2024; October 23-27, 2024; San Diego, USA. FR-OR63; 6. Jenkinson C et al. Poster presented at: ISN World Congress of Nephrology; April 12-15, 2019; Melbourne, Australia. SAT-010; 7. Reilly C et al. *Am J Physiol Renal Physiol*. 2024;326:F862-F875; 8. Jenkinson C et al. Presentation at: International Symposium on IgANephropathy; September 27-29, 2018; Buenos Aires, Argentina; 9. Nagasawa H et al. *Nephrol Dial Transplant*. 2024;39:1494-1503; 10. Rovin BH et al. *Lancet*. 2023;402(10417):2077-2090.